Patents by Inventor Stephen J. ELLIMAN

Stephen J. ELLIMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952590
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: April 9, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11952589
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: April 9, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11926848
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: March 12, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11918687
    Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: March 5, 2024
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Jack Kavanaugh, Larry Couture
  • Patent number: 11903997
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 20, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Patent number: 11884936
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: January 30, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Publication number: 20230332106
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Application
    Filed: June 5, 2023
    Publication date: October 19, 2023
    Inventor: Stephen J. ELLIMAN
  • Publication number: 20230323307
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Application
    Filed: June 5, 2023
    Publication date: October 12, 2023
    Inventor: Stephen J. ELLIMAN
  • Publication number: 20230313142
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Application
    Filed: June 5, 2023
    Publication date: October 5, 2023
    Inventor: Stephen J. ELLIMAN
  • Publication number: 20220288129
    Abstract: Provided herein are methods and compositions for monocyte and macrophage polarization including methods for use in treating a disease or disorder.
    Type: Application
    Filed: August 20, 2020
    Publication date: September 15, 2022
    Inventors: Stephen J. ELLIMAN, Senthilkumar ALAGESAN, Laura M DEEDIGAN
  • Publication number: 20220228122
    Abstract: Disclosed herein are methods of isolating SDC2+ stromal stem cells and exosomes from SDC2+ stromal stem cells by expression of surface marker CD39. Also disclosed herein are stromal stem cells and exosomes isolated by said methods.
    Type: Application
    Filed: January 28, 2022
    Publication date: July 21, 2022
    Inventors: Stephen J. ELLIMAN, Jack KAVANAUGH, Larry A. COUTURE, Lisa O'FLYNN
  • Publication number: 20220112466
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Application
    Filed: September 9, 2021
    Publication date: April 14, 2022
    Inventor: Stephen J. Elliman
  • Patent number: 11268067
    Abstract: Disclosed herein are methods of isolating SDC2+ stromal stem cells by expression of surface marker CD39. Also disclosed herein are stromal stem cells isolated by said methods.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 8, 2022
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Jack Kavanaugh, Larry A. Couture, Lisa O'Flynn
  • Patent number: 11142747
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 12, 2021
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Publication number: 20210154235
    Abstract: Provided herein are stromal stem cell therapeutics and methods of use in treating disease.
    Type: Application
    Filed: May 30, 2018
    Publication date: May 27, 2021
    Inventors: Larry A. COUTURE, Stephen J. ELLIMAN, Lisa O'FLYNN, Jack KAVANAUGH
  • Publication number: 20200149012
    Abstract: Disclosed herein are methods of isolating SDC2+ stromal stem cells and exosomes from SDC2+ stromal stem cells by expression of surface marker CD39. Also disclosed herein are stromal stem cells and exosomes isolated by said methods.
    Type: Application
    Filed: July 12, 2018
    Publication date: May 14, 2020
    Inventors: Stephen J. ELLIMAN, Jack KAVANAUGH, Larry A. COUTURE, Lisa O'FLYNN
  • Publication number: 20190262421
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Application
    Filed: October 9, 2018
    Publication date: August 29, 2019
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Publication number: 20190015331
    Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 17, 2019
    Inventors: Stephen J. ELLIMAN, Jack Kavanaugh, Larry COUTURE
  • Patent number: 10124038
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: November 13, 2018
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Publication number: 20180298341
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 18, 2018
    Inventor: Stephen J. Elliman